FOXM1 and leukemia: At 3 weeks post-transplantation, leukemia burden, as determined by in vivo imaging, was reduced dramatically in MA9-Foxm1 CKO recipient mice by more than 10-fold as compared to MA9-Foxm1fl/fl recipient mice (Fig. 3d).